EC approves Celgene's pomalidomide

The European Commission approved Imnovid pomalidomide from Celgene Corp. (NASDAQ:CELG) to treat patients with relapsed and refractory multiple myeloma (MM). Imnovid is approved in combination with dexamethasone in adults who have received at least two prior therapies, including both Velcade bortezomib and Celgene's Revlimid lenalidomide, and whose disease progressed while on their last therapy. FDA granted accelerated approval to the thalidomide analog as Pomalyst for the indication last February (see BioCentury Extra, Feb. 28, 2012).

Celgene was up $0.07 to $142.07 on Friday. ...